湖州地区HBV自然发生基因型耐药突变：单中心研究

StephenW

Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study
         

    Abstract
    Metrics
    Get Permission

Authors Qian F, Zou W, Qin J, Li D

Received 25 August 2017

Accepted for publication 6 October 2017

Published 14 December 2017 Volume 2017:10 Pages 507—509

DOI https://doi.org/10.2147/IDR.S149992

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Dr Joachim Wink

Fuchu Qian,1 Weihua Zou,2 Jiqu Qin,1 Dongli Li1

1Huzhou Key Laboratory of Molecular Medicine, 2Department of Laboratory Medicine, Huzhou Central Hospital, Huzhou, China

China is an area with highly endemic hepatitis B virus (HBV) infection, with an estimated 93 million HBV carriers, resulting in approximately 330,000 deaths annually.1 The predominant HBV genotypes in China are genotype B and C. Currently,  nucleos(t)ide analogs are used for anti-HBV treatment. However, prolonged antiviral therapy may lead to drug resistance, which is associated with mutations in the reverse transcriptase region of the HBV genome. Several studies have shown that drug-resistant mutations existed in treatment-naïve patients with chronic hepatitis B (CHB). However, the prevalence rates of natural drug-resistant mutations varied in different reports.2,3 Furthermore, the prevalence and clinical profile of natural drug-resistant mutations in CHB patients are not quite clear. Thus, the purpose of this study was to investigate the prevalence and clinical feature of natural drug-resistant mutations among treatmentnaïve CHB patients in a tertiary hospital in Huzhou, eastern China.

In summary, the present study shows that the primary
drug-resistance mutations (rtM204V/I, rtA181T/V,
and rtN236T) and secondary drug-resistance mutations
(rtL80V/I, rtV173L, and rtL180M) existed in treatment naïve
CHB patients in Huzhou, eastern China. Considering
that pre-existing drug-resistant mutations may affect the
efficiency of antiviral therapy, it is necessary to monitor the
nucleos(t)ide analog resistance mutations before antiviral
therapy.

StephenW

湖州地区HBV自然发生基因型耐药突变：单中心研究
         

    抽象
    度量
    获取权限

作者：钱，，邹炜，秦俭，李德

2017年8月25日收到

已于2017年10月6日接受发布

2017年12月14日发布第2017卷：10页507-509

DOI https://doi.org/10.2147/IDR.S149992

检查剽窃是的

由单盲评审

同行评审由Akshita Wason博士批准

同行评审意见3

编辑批准出版物：Joachim Wink博士

钱富初，邹卫华，秦继群，李东立

湖州市湖州市中心医院分子医学重点实验室2，湖州市中心医院检验科2

中国是乙型肝炎病毒（HBV）感染高发地区，估计有9300万乙肝病毒携带者，每年约有33万人死亡。中国主要的乙型肝炎病毒基因型为B型和C型。目前，核苷酸类似物用于抗HBV治疗。然而，延长的抗病毒治疗可能导致耐药性，这与HBV基因组逆转录酶区域的突变有关。一些研究表明，在慢性乙型肝炎（CHB）治疗初治患者中存在耐药突变。然而，不同报道中天然耐药突变的患病率不尽相同[2,3]。此外，CHB患者天然耐药突变的患病率和临床特征还不十分清楚。因此，本研究旨在探讨中国东部湖州地区三级医院CHB患者自然耐药突变的流行和临床特征。

总之，目前的研究表明，小学
药物抗性突变（rtM204V / I，rtA181T / V，
和rtN236T）和继发性耐药突变
（rtL80V / I，rtV173L和rtL180M）存在于治疗中
CHB患者在中国东部湖州。考虑到
预先存在的耐药突变可能会影响
抗病毒治疗的效率，有必要监测
核苷（t）ide模拟抗药性突变之前的抗病毒药物
治疗。

StephenW

https://www.dovepress.com/getfile.php?fileID=39720